Sanmarti R, Veale DJ, Martin‐Mola E, Escudero‐Contreras A, González C, Ercole L, Alonso R, Fonseca JE, Alcañiz C, Álvaro‐Gracia JM, Balsa A, Pablos JL, Miguel CD, Rodríguez JM, Alves J, Aurrecoechea E, Calvo J, Belzunegui J, Blanco F, Caliz R, Calvo J, Ivorra JR, Canhão H, Santos H, Chamizo E, Pino J, Delgado C, Díaz C, Nebro AF, Fraser A, Gomez A, Hernández B, Navarro F, Povedano J, Mas AJ, Kane D, Whelan B, Marras C, Moreno J, Venegas JP, Pombo M, Riera E, Rosas A, Ryan J, Santos J, Santos M, Tornero J, Tovar JV, Ucar E, Vasconcelos C, Veiga R, Vela P. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open‐Label Trial. Arthritis Rheumatol 2019;71:1616-1625. [DOI: 10.1002/art.40905] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Accepted: 04/02/2019] [Indexed: 12/20/2022]